Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:ELVNNASDAQ:HROWNASDAQ:OVAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$30.23+3.0%$28.12$23.23▼$42.29$971.35M0.63429,690 shs430,854 shsELVNEnliven Therapeutics$16.86-5.4%$18.84$13.30▼$30.03$827.25M1.07263,676 shs473,950 shsHROWHarrow$28.41+10.9%$25.02$15.97▼$59.23$1.04B0.41498,095 shs633,665 shsOVASOvaScience$6.85+5.4%$12.74$0.66▼$1.52$245.44M3.11163,131 shs118,331 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical0.00%+4.64%+11.92%+1.92%-11.04%ELVNEnliven Therapeutics0.00%-8.91%+2.00%-22.23%-29.75%HROWHarrow0.00%+16.43%+18.42%-6.61%+78.40%OVASOvaScience+5.38%+5.55%-5.52%+636.48%+102.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.0194 of 5 stars3.40.00.03.03.40.82.5ELVNEnliven Therapeutics2.5511 of 5 stars3.62.00.00.01.94.20.0HROWHarrow2.2634 of 5 stars3.51.00.00.02.62.50.6OVASOvaScienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.80Moderate Buy$43.8044.89% UpsideELVNEnliven Therapeutics 3.20Buy$37.25120.94% UpsideHROWHarrow 3.00Buy$61.25115.59% UpsideOVASOvaScience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OVAS, ELVN, HROW, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/12/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$57.00 ➝ $60.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/1/2025HROWHarrowB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$69.00 ➝ $65.003/31/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.003/24/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.003/18/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$664.28M1.46$10.95 per share2.76$5.99 per share5.05ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AHROWHarrow$212.86M4.90N/AN/A$2.01 per share14.13OVASOvaScience$290K846.33N/AN/A$1.80 per share3.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$48.15M$1.2213.035.02N/A14.78%104.67%18.38%N/AELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%N/AHROWHarrow-$24.41M-$0.56N/A71.03N/A-19.75%-45.57%-8.87%N/AOVASOvaScience-$50.97MN/A0.00∞N/A-10,128.37%-47.06%-42.39%N/ALatest OVAS, ELVN, HROW, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million3/27/2025Q4 2024HROWHarrow$0.11$0.25+$0.14$0.24$66.01 million$66.83 million3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million2/27/2025Q4 2024COLLCollegium Pharmaceutical$1.54$1.63+$0.09$0.36$179.68 million$181.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.430.970.88ELVNEnliven TherapeuticsN/A17.4417.44HROWHarrow3.231.551.44OVASOvaScienceN/A12.6212.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AELVNEnliven Therapeutics95.08%HROWHarrow72.76%OVASOvaScience22.52%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%ELVNEnliven Therapeutics29.20%HROWHarrow13.67%OVASOvaScience7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableELVNEnliven Therapeutics5049.07 million34.59 millionOptionableHROWHarrow18236.69 million30.75 millionOptionableOVASOvaScienceN/A35.83 millionN/ANot OptionableOVAS, ELVN, HROW, and COLL HeadlinesRecent News About These CompaniesAssisted Reproductive Technology Market to Surpass USD 40.67 Billion by 2031 | SkyQuest TechnologyAugust 9, 2024 | finance.yahoo.comGlobal Fertility Services Market Report 2024-2032, by Cause of Infertility, Procedure, Service, End-User and RegionMay 21, 2024 | uk.finance.yahoo.comIn Vitro Fertilization Market Will Increase USD 40.6 Billion By 2032 With Around 7.8% CAGRApril 2, 2024 | pharmiweb.comInfertility Services Market Set for Remarkable Expansion, Worth USD 3.8 Billion by 2033 | Market.usMarch 13, 2024 | pharmiweb.comGeneral Catalyst Group V LP's Net WorthFebruary 11, 2024 | benzinga.comGlobal In Vitro Fertilization Market Size To Worth USD 39.12 Billion By 2032 | CAGR of 5.5%December 7, 2023 | finance.yahoo.comOvascience (OVAS) Stock Drops After Pricing Public OfferingNovember 4, 2023 | thestreet.comGlobal Retail Automation Market Size 2023-2027 | Drivers, Product Types, Applications, Growth Analysis and ForecastJune 30, 2023 | finance.yahoo.comTMRW Life Sciences Names Louis Villalba Chief Executive OfficerJune 27, 2023 | markets.businessinsider.comIVF Devices and Consumables Market Research Report 2023 Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2030June 22, 2023 | marketwatch.comOcuTerra Appoints Bill Steinkrauss as Chief Financial OfficerJune 1, 2023 | finance.yahoo.comIVF Market Business Approaches by 2030May 15, 2023 | marketwatch.comIVF Devices Market is Predicted to Reach US$ 6367 million by 2027 ... - StreetBuzzMay 14, 2023 | news.google.comSemen Analysis System Market SWOT analysis of key factors to ... - StreetBuzzMay 13, 2023 | news.google.comDonor Egg IVF Treatment Market Statistics, Share Price, Growth ... - Digital JournalMay 12, 2023 | news.google.comIVF Instruments Market Insights, Rising Trends and Global Demand ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comAssisted Reproductive Technologies (ART) Market Size Growth and ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comAssisted Reproductive Technology Market Expected to Reach USD 54.75 Billion by 2028 at a 9.7% CAGR - openPRMay 10, 2023 | news.google.comGlobal Assisted Reproductive Technology Market Global Segments ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comIn Vitro Fertilization Market is Expected to Reach USD 36.51 Billion ... - EIN NewsMay 9, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOVAS, ELVN, HROW, and COLL Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$30.23 +0.89 (+3.03%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$30.24 +0.01 (+0.03%) As of 05/16/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Enliven Therapeutics NASDAQ:ELVN$16.86 -0.96 (-5.39%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$16.89 +0.03 (+0.18%) As of 05/16/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Harrow NASDAQ:HROW$28.41 +2.79 (+10.89%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$27.82 -0.59 (-2.08%) As of 05/16/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.OvaScience NASDAQ:OVASMillendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
